False-negative results can also occur, particularly in prostate cancer subtypes with little or no PSMA expression, including poorly differentiated or neuroendocrine tumors, or in lesions that have lost expression after extensive treatment. This evidence concerns the gene FOLH1 and prostate carcinoma.